Cytosorbents

Cytosorbents R&D per Employee

The R&D Spending per Employee of Cytosorbents (CTSO) as of Oct 27, 2026 is 39,418.60 USD. In the previous year, R&D Spending per Employee was 58,968.99 USD — a change of -33.15% (lower).

R&D per Employee

39,418.60USD

YoY

-33.15%

Last updated:

R&D Spending per Employee of Cytosorbents is 2025 39,418.60 USD. R&D Spending per Employee of Cytosorbents was 2024 58,968.99 USD. It decreases by -33.15% lower compared to the previous year.

The Cytosorbents R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
59,868.43 USD
Jan 1, 2019
93,736.43 USD
Jan 1, 2020
68,294.57 USD
Jan 1, 2021
126,983.95 USD
Jan 1, 2022
117,200.83 USD
Jan 1, 2023
120,887.15 USD
Jan 1, 2024
58,968.99 USD
Jan 1, 2025
39,418.60 USD
The Cytosorbents R&D per Employee history
YEARR&D per EmployeeYoY
39,418.60USD-33.15%
58,968.99USD-51.22%
120,887.15USD+3.15%
117,200.83USD-7.70%
126,983.95USD+85.94%
68,294.57USD-27.14%
93,736.43USD+56.57%
59,868.43USD+90.72%
31,390.98USD-15.35%
37,081.33USD+23.57%
30,008.29USD+59.17%
18,852.71USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytosorbents Stock analysis

What does Cytosorbents do? Cytosorbents Corp is a US-American company specialized in the development of medical technologies for the treatment of life-threatening diseases and injuries. It was founded in 1997 by Dr. Phillip Chan. Originally, Cytosorbents specialized in the development of therapeutics for cancer therapy. After several development phases and a realignment of the company, they eventually focused on developing medical products for intensive care medicine. The business model of Cytosorbents is based on the development and marketing of blood purification systems that remove harmful substances and toxins from the blood. This can treat life-threatening diseases and complications such as sepsis, organ failure, or severe burns. An important product of Cytosorbents is the Cytosorb system, which consists of an extracorporeal blood purification device. The system is used to attenuate disease-related inflammatory reactions and remove harmful substances from the blood. This is intended to prevent complications and improve the survival of patients. Cytosorbents offers the Cytosorb system, among other things, for use in intensive and emergency medicine. It is used, among other things, to treat sepsis, which can lead to life-threatening organ failure. It is also used to treat severe burns, to rid the blood of toxic substances and inflammatory mediators, and thus accelerate the healing process. In addition to the Cytosorb system, the company also offers other medical products such as the HemoDefend plasma exchanger. This system is used to purify blood plasma from harmful substances while retaining the beneficial components in the plasma. It is used, among other things, to treat patients in need of a blood transfusion. Cytosorbents has experienced significant expansion in recent years. The company has established subsidiaries in Europe, Asia, and the Middle East and works closely with major hospitals and medical facilities. Additionally, the company has formed several partnerships with leading medical technology companies to expand the use of its technology in other areas. In summary, Cytosorbents is an innovative company specializing in the development of medical devices for the treatment of life-threatening diseases. The company has expanded significantly in recent years and collaborates with renowned hospitals and medical facilities. In the future, Cytosorbents will continue to refine and improve its technologies to help even more patients. Cytosorbents is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytosorbents stock

R&D Spending per Employee of Cytosorbents is 39,418.60 USD in 2025.

R&D Spending per Employee of Cytosorbents changed from 58,968.99 USD to 39,418.60 USD, representing a -33.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Cytosorbents since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Cytosorbents historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Cytosorbents

All Key Metrics — Cytosorbents